A severe case of rhabdomyolysis after Moderna mRNA anti-COVID-19 vaccine with a literature review

Maria Sheka; Yann Coattrenec; Kuntheavy Ing Lorenzini; Mathieu Nendaz

doi:10.1002/ccr3.7184

A severe case of rhabdomyolysis after Moderna mRNA anti-COVID-19 vaccine with a literature review

Clin Case Rep. 2023 May 16;11(5):e7184. doi: 10.1002/ccr3.7184. eCollection 2023 May.

Authors

Maria Sheka¹, Yann Coattrenec^{2

3}, Kuntheavy Ing Lorenzini^{3

4}, Mathieu Nendaz^{1

3}

Affiliations

¹ Department of Medicine, Division of General Internal Medicine Geneva University Hospitals Geneva Switzerland.
² Department of Medicine, Division of Immunology and Allergology Geneva University Hospitals Geneva Switzerland.
³ Department of Medicine Geneva University Hospitals and Faculty of Medicine, University of Geneva Geneva Switzerland.
⁴ Department of Anesthesiology, Pharmacology, Division of Clinical Pharmacology and Toxicology, Intensive Care and Emergency Medicine Geneva University Hospitals Geneva Switzerland.

Abstract

The identification of rhabdomyolysis as a potential fatal adverse reaction to recent COVID-19 vaccines is essential. As the symptoms of rhabdomyolysis are not specific, the threshold to actively search for this complication should be low.

Keywords: 2019‐nCoV vaccine mRNA‐1273; COVID‐19; COVID‐19 vaccines; drug‐related side effects and adverse reactions; molecular mechanisms of pharmacological action; rhabdomyolysis.

Publication types

Case Reports